Overview of pathogenesis of systemic sclerosis.

The aetiology of SSc is subject to ongoing research, as the precise events that underlie the development of this disease remain unclear. The pathogenesis is known to involve endothelium, epithelium, fibroblasts, innate and adaptive immune systems and their component immunological mediators. Endothelial cell damage may be the initiating factor, but the precise triggering event(s) remain elusive. Angiogenesis also appears to be dysregulated. Vasculopathy shows similarities in different organs (e.g. pulmonary arterial hypertension, renal disease, digital tip ulcers). Endothelin-1 is a potent mediator of vasculopathy, and hence represents a highly relevant target for intervention of vascular features in SSc.

[1]  B. Hinz,et al.  Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix , 2007, The Journal of cell biology.

[2]  D. Abraham,et al.  How does endothelial cell injury start? The role of endothelin in systemic sclerosis , 2007, Arthritis research & therapy.

[3]  C. Denton.  Therapeutic targets in systemic sclerosis , 2007, Arthritis research & therapy.

[4]  A. Koch,et al.  Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis , 2007, Arthritis research & therapy.

[5]  C. Denton,et al.  Scleroderma renal crisis: patient characteristics and long-term outcomes. , 2007, QJM : monthly journal of the Association of Physicians.

[6]  P. Shaul,et al.  Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. , 2007, American journal of respiratory cell and molecular biology.

[7]  Vineeth Rajkumar,et al.  New developments in fibroblast and myofibroblast biology: Implications for fibrosis and scleroderma , 2007, Current rheumatology reports.

[8]  Giulio Gabbiani,et al.  The myofibroblast: one function, multiple origins. , 2007, The American journal of pathology.

[9]  M. Fujimoto,et al.  B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. , 2006, The American journal of pathology.

[10]  D. Sheppard,et al.  Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix , 2006, Proceedings of the National Academy of Sciences.

[11]  Howard Y. Chang,et al.  Anatomic Demarcation by Positional Variation in Fibroblast Gene Expression Programs , 2006, PLoS genetics.

[12]  Li Jin,et al.  Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. , 2006, Arthritis and rheumatism.

[13]  A. Gabrielli,et al.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.

[14]  B. Willis,et al.  Epithelial origin of myofibroblasts during fibrosis in the lung. , 2006, Proceedings of the American Thoracic Society.

[15]  M. Mayes,et al.  Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. , 2006, Arthritis and rheumatism.

[16]  Yunliang Chen,et al.  Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. , 2006, Arthritis and rheumatism.

[17]  K. Csiszȧr,et al.  Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis , 2005, Arthritis research & therapy.

[18]  S. Black,et al.  Endothelin-1 in Congenital Heart Disease , 2005, Pediatric Research.

[19]  Till Acker,et al.  Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.

[20]  P. Helmbold,et al.  Hyperplasia of dermal microvascular pericytes in scleroderma * , 2004, Journal of cutaneous pathology.

[21]  M. Humbert,et al.  Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[22]  M. Fujimoto,et al.  Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. , 2004, Arthritis and rheumatism.

[23]  T. Krieg,et al.  Expression of pro-inflammatory markers by human dermal fibroblasts in a three-dimensional culture model is mediated by an autocrine interleukin-1 loop. , 2004, The Biochemical journal.

[24]  M. Aringer,et al.  Increased transendothelial migration of scleroderma lymphocytes , 2004, Annals of the rheumatic diseases.

[25]  E. Rhew,et al.  Scleroderma renal crisis: New insights and developments , 2004, Current rheumatology reports.

[26]  Arnold I. Caplan,et al.  Fibroblast heterogeneity: more than skin deep , 2004, Journal of Cell Science.

[27]  David Botstein,et al.  Systemic and cell type-specific gene expression patterns in scleroderma skin , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Conforti,et al.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.

[29]  S. Jimenez,et al.  Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, The Journal of Immunology.

[30]  H. Schäfers,et al.  Selective Upregulation of Endothelin B Receptor Gene Expression in Severe Pulmonary Hypertension , 2002, Circulation.

[31]  D. Margolis,et al.  Identification of clonal T cells in the blood of patients with systemic sclerosis: positive correlation with response to photopheresis. , 2001, Archives of dermatology.

[32]  J. Pearson,et al.  Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. , 2001, The Journal of investigative dermatology.

[33]  T. Tedder,et al.  Quantitative Genetic Variation in CD19 Expression Correlates with Autoimmunity1 , 2000, The Journal of Immunology.

[34]  L. Hornez,et al.  Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.

[35]  V. Rajkumar,et al.  Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. , 1999, Arthritis and rheumatism.

[36]  R. D. du Bois,et al.  Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. , 1997, The American journal of pathology.

[37]  J. Piette,et al.  Antiendothelial cell antibodies: useful markers of systemic sclerosis. , 1997, The American journal of medicine.

[38]  M. Greaves,et al.  Antibodies to membranes of endothelial cells and fibroblasts in scleroderma , 1996, Clinical and experimental immunology.

[39]  E. Leroy.  SYSTEMIC SCLEROSIS : A Vascular Perspective , 1996 .

[40]  T. Medsger,et al.  Soluble serum interleukin 2 receptors in patients with systemic sclerosis. , 1996, The Journal of rheumatology.

[41]  C. Ferri,et al.  Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? , 1996, The Journal of rheumatology.

[42]  R. Lappe,et al.  Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle. , 1993, Biochemical and biophysical research communications.

[43]  M. Zamora,et al.  Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. , 1992, The American journal of physiology.

[44]  B. Fanburg,et al.  Endothelin 1: Mitogenic Activity on Pulmonary Artery Smooth Muscle Cells and Release from Hypoxic Endothelial Cells , 1992, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[45]  K. Dittmann,et al.  Human skin fibroblasts in vitro differentiate along a terminal cell lineage. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Woo,et al.  Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. , 1988, Clinical and experimental immunology.

[47]  R. Behringer,et al.  Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. , 2007, Arthritis and rheumatism.

[48]  H. Ihn,et al.  Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. , 1998, The Journal of investigative dermatology.

[49]  H. Ihn,et al.  Increased Expression of TGF-β Receptors by Scleroderma Fibroblasts: Evidence for Contribution of Autocrine TGF-β Signaling to Scleroderma Phenotype , 1998 .

[50]  E. CARwni LEROYwith,et al.  Increased Collagen Synthesis by Scleroderma Skin Fibroblasts In Vitro A POSSIBLE DEFECT IN THE REGULATION OR ACTIVATION OF THE SCLERODERMA FIBROBLAST , 2022 .